Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)
NCT00050154
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
82
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
ZARNESTRA, tipifarnib, R115777
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.